Corcept Therapeutics/$CORT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
- Ticker
- $CORT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 730
- Headquarters
- Redwood City, United States
- Website
- www.corcept.com
CORT Metrics
BasicAdvanced
$13B
261.30
$0.45
0.46
-
Price and volume
Market cap
$13B
Beta
0.46
52-week high
$126.38
52-week low
$28.66
Average daily volume
1.4M
Financial strength
Current ratio
2.859
Quick ratio
2.504
Long term debt to equity
0.011
Total debt to equity
0.013
Profitability
EBITDA (TTM)
8.084
Gross margin (TTM)
98.30%
Net profit margin (TTM)
6.64%
Operating margin (TTM)
0.77%
Effective tax rate (TTM)
-109.27%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
0.47%
Return on equity (TTM)
8.23%
Valuation
Price to earnings (TTM)
261.3
Price to revenue (TTM)
14.876
Price to book
18.13
Price to tangible book (TTM)
18.13
Price to free cash flow (TTM)
115.593
Free cash flow yield (TTM)
0.87%
Free cash flow per share (TTM)
1.025
Growth
Revenue change (TTM)
16.02%
Earnings per share change (TTM)
-59.30%
3-year revenue growth (CAGR)
24.73%
10-year revenue growth (CAGR)
29.22%
3-year earnings per share growth (CAGR)
-17.60%
10-year earnings per share growth (CAGR)
47.69%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
Analyst projections of the future price of Corcept Therapeutics stock.
Bulls say / Bears say
Lifyorli generated $47.6 million in its first quarter on sale, with more than 1,300 patients starting treatment. Q2 revenue rose 32% year on year and Corcept raised its 2026 revenue guidance to $1.1–$1.2 billion, giving the new launch a strong early commercial start. (Corcept Therapeutics)
The European Medicines Agency’s expert committee recommended approval of Lifyorli for platinum-resistant ovarian cancer, based on trials that showed better progression-free and overall survival. A final European Commission decision was expected in Q4 2026, offering a route to expand beyond the US market. (Business Wire)
The FDA has received Corcept’s resubmitted relacorilant application for Cushing’s syndrome, supported by additional analyses requested by the agency, with a six-month review expected. Approval could add another treatment to Corcept’s established Cushing’s franchise, although the outcome remains uncertain. (BioSpace)
A federal appeals court ruled against Corcept in its effort to block Teva’s generic Korlym, weakening the company’s ability to protect the branded drug from generic competition. That could put pressure on a key source of sales. (The Motley Fool)
The FDA previously rejected relacorilant for Cushing’s syndrome, saying the evidence was not sufficient for approval. Corcept’s resubmission adds analyses of existing data rather than new prospectively collected evidence, leaving the December review exposed to regulatory uncertainty. (PharmaDeviceNews)
Despite Lifyorli’s launch, Korlym and its authorised generic still accounted for $208.6 million of Corcept’s $256.1 million in Q2 revenue. The company therefore remains heavily reliant on a franchise exposed to generic competition. (Corcept Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
Upcoming events
No upcoming events
CORT News
AllArticlesVideos
Funds containing CORT
AllUSDGBPEUR
Fund name | Fund size | $CORT weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.34% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.34% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.19% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.19% |
iShares MSCI World Small Cap$WSML | $9B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.